Applied dna's linearx subsidiary stands ready to support the reshoring of drug development and manufacturing with u.s.-produced synthetic dna

- pivot to u.s.-based supply chain for critical input materials completed - stony brook, ny / access newswire / april 21, 2025 / applied dna sciences, inc. (nasdaq:apdn) (applied dna or the "company"), a leader in pcr-based dna technologies, today announced that linearx, inc., the company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its lineadna™ and lineaivt™ platforms from u.s.-based suppliers. the initiative, undertaken in response to the 2024 biosecure act and customer demand for a u.s.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the u.s. in response to potential tariff impacts and to ensure a stable supply chain.
DNA Ratings Summary
DNA Quant Ranking